MDWD (MediWound) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDWD MediWound Ltd MDWD
56 GF Score
Price $14.38
GF Value $12.59
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

MDWD
56GF Score
MediWound Ltd MDWD
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $14.38 is trading 14.2% above its estimated GF Value™ of $12.59. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • Cash Payments:
  • GF Value™: $12.59 vs. price of $14.38 (14.2% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for MDWD

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.38
Price
$12.59
GF Value